Patents by Inventor Tsuguo Kubota
Tsuguo Kubota has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20130202607Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: August 13, 2012Publication date: August 8, 2013Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Norihiko SHIRAISHI, Akiko FURUYA, Hiroe TOKI, Hiroshi ANDO, Masayo SUZUKI, Tsuguo KUBOTA
-
Patent number: 8501180Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: January 18, 2011Date of Patent: August 6, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventor: Tsuguo Kubota
-
Publication number: 20130177944Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: January 31, 2013Publication date: July 11, 2013Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
-
Patent number: 8399621Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: December 28, 2009Date of Patent: March 19, 2013Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tomoaki Nakagawa, Sayaka Hori, Rinpei Niwa, Tsuguo Kubota, Kazuhiro Masuda, Kazuyasu Nakamura
-
Patent number: 8333967Abstract: An anti-A? oligomer humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of A? amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.Type: GrantFiled: August 9, 2010Date of Patent: December 18, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tsuguo Kubota, Nobuyuki Suzuki
-
Patent number: 8303954Abstract: An anti-cognitive dysfunction agent comprising a humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers and a fragment thereof as an active ingredient, and an therapeutic antibody which can be treat Alzheimer's disease by specifically binding amyloid ? protein oligomer (A? oligomer) which is considered to be a cause of Alzheimer's disease are required. The present invention can provide an anti-A? oligomer humanized antibody and a method for treating Alzheimer's disease using the humanized antibody. An agent for treating Alzheimer's disease; an agent for suppressing formation of neuritic plaque; an inhibitor of formation of A? amyloid fiber; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the humanized antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the humanized antibody.Type: GrantFiled: August 9, 2010Date of Patent: November 6, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Tsuguo Kubota, Nobuyuki Suzuki
-
Publication number: 20120237518Abstract: The present invention relates to a monoclonal antibody or an antibody fragment thereof, which binds to the extracellular region of human Trop-2 with high affinity and exhibits high ADCC activity and high antitumor activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent or a diagnostic agent using the antibody fragment thereof.Type: ApplicationFiled: June 10, 2011Publication date: September 20, 2012Applicants: KYOWA HAKKO KIRIN CO., LTD, SAPPORO MEDICAL UNIVERSITYInventors: Miki YAMAGUCHI, Kazunori Kato, Hirofumi HAMADA, Kazuyasu NAKAMURA, Yoshiyuki SUGIMOTO, Tsuguo KUBOTA, Masahiro IKEDA
-
Patent number: 8268592Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: GrantFiled: July 17, 2009Date of Patent: September 18, 2012Assignee: Kyowa Hakko Kirin Co., LtdInventors: Norihiko Shiraishi, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Publication number: 20120189617Abstract: The present invention provides an anti-human TIM-3 antibody which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure thereof and exhibits higher effector activity such as an antibody-dependent cellular cytotoxicity (ADCC activity) for diseases relating to a human TIM-3 expressing cell. The present invention provides a monoclonal antibody or antibody fragment thereof which binds to the amino acid sequence of the extracellular region of TIM-3 or its three-dimensional structure and exhibits ADCC activity; a hybridoma which produces the antibody; a DNA encoding the antibody; a vector comprising the DNA; a transformant which is obtainable by introducing the vector; a method for producing the antibody or the antibody fragment thereof which comprises using the hybridoma or the transformant; a therapeutic agent and a diagnostic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: June 13, 2011Publication date: July 26, 2012Applicants: KYUSHU UNIVERSITY, NATIONAL UNIVERSITY CORPORATION, KYOWA HAKKO KIRIN CO., LTDInventors: Shin-ichiro TAKAYANAGI, Hitomi TOMURA, Tomonori TAWARA, Yoshimasa INAGAKI, Tsuguo KUBOTA, Koichi AKASHI, Yoshikane KIKUSHIGE
-
Publication number: 20120093805Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: December 28, 2010Publication date: April 19, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventor: Tsuguo KUBOTA
-
Publication number: 20120039904Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (ASCT2) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of system ASC amino acid transporter 2 (ASCT2) and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: January 18, 2011Publication date: February 16, 2012Applicant: KYOWA HAKKO KIRIN CO., LTDInventor: Tsuguo KUBOTA
-
Publication number: 20120009180Abstract: An anti-cognitive dysfunction agent comprising a humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers and a fragment thereof as an active ingredient, and an therapeutic antibody which can be treat Alzheimer's disease by specifically binding amyloid ? protein oligomer (A? oligomer) which is considered to be a cause of Alzheimer's disease are required. The present invention can provide an anti-A? oligomer humanized antibody and a method for treating Alzheimer's disease using the humanized antibody. An agent for treating Alzheimer's disease; an agent for suppressing formation of neuritic plaque; an inhibitor of formation of A? amyloid fiber; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the humanized antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the humanized antibody.Type: ApplicationFiled: August 9, 2010Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tsuguo KUBOTA, Nobuyuki SUZUKI
-
Publication number: 20120009179Abstract: An anti-A? oligomer humanized antibody which does not bind to A? monomers and specifically binds only to A? oligomers; an anti-cognitive dysfunction agent, an agent for treating Alzheimer's disease, an agent for suppressing formation of neuritic plaque and an inhibitor of formation of A? amyloid fiber comprising the antibody as an active ingredient; a method for at least one of preventing and treating cognitive dysfunction or Alzheimer's disease, comprising the step of administering the antibody; and a method for suppressing progression of Alzheimer's disease, comprising the step of administering the antibody.Type: ApplicationFiled: August 9, 2010Publication date: January 12, 2012Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tsuguo KUBOTA, Nobuyuki SUZUKI
-
Publication number: 20100310573Abstract: An anti-CD4 antibody which binds to CD4, has a high affinity and has a high effector activity, such as an antibody-dependent cellular cytotoxicity (ADCC activity) or complement-dependent cellular cytotoxicity (CDC activity), is required for a disease relating to a CD4-expressing cell. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which binds to a CD4 extracellular region with high affinity and also exhibits a high ADCC activity or a high CDC activity; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof or a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: December 28, 2009Publication date: December 9, 2010Applicant: KYOWA HAKKO KIRIN CO., LTD.Inventors: Tomoaki NAKAGAWA, Sayaka HORI, Rinpei NIWA, Tsuguo KUBOTA, Kazuhiro MASUDA, Kazuyasu NAKAMURA
-
Publication number: 20100196392Abstract: An object of the present invention is to provide a monoclonal antibody which is useful for treating or diagnosing a disease relating to system ASC amino acid transporter 2 (hereinafter, referred to as “ASCT2”) or a method using the antibody. The present invention provides a monoclonal antibody which specifically recognizes a native three-dimensional structure of an extracellular region of ASCT2 and binds to the extracellular region, or an antibody fragment thereof; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which contains the DNA; a transformant obtainable by introducing the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a therapeutic agent using the antibody or the antibody fragment thereof, and a diagnostic agent using the antibody or the antibody fragment thereof.Type: ApplicationFiled: July 17, 2009Publication date: August 5, 2010Applicant: Kyowa Hakko Kirin Co., Ltd.Inventors: Norihiko SHIRAISHI, Akiko Furuya, Hiroe Toki, Hiroshi Ando, Masayo Suzuki, Tsuguo Kubota
-
Publication number: 20100173324Abstract: The present invention provides a monoclonal antibody which specifically recognizes CD27 containing an O-linked sugar chain to which galactose is not bound and binds to its extracellular region, or a method for using the same. The present invention can provide a monoclonal antibody or an antibody fragment thereof, which specifically recognizes a polypeptide encoded by CD27 gene containing an O-linked sugar chain to which galactose is not bound, and binds to its extracellular region; a hybridoma which produces the antibody; a DNA which encodes the antibody; a vector which comprises the DNA; a transformant obtainable by transforming the vector; a process for producing an antibody or an antibody fragment thereof using the hybridoma or the transformant; and a diagnostic agent or a therapeutic agent comprising the antibody or the antibody fragment thereof as an active ingredient.Type: ApplicationFiled: June 30, 2009Publication date: July 8, 2010Applicant: KYOWA HAKKO KIRIN CO., LTDInventors: Katsuhiro MORI, Naoko HIURA, Tsuguo KUBOTA, Akiko FURUYA, Yutaka KANDA, Mitsuo SATOH
-
Patent number: 6164224Abstract: A cloth cutting knife 16 is structured such that the length of the cutting edge thereof is set shorter than the length of the side sewing portions of a buttonhole to be formed, and a buttonhole having a length corresponding to the length of the right and left side sewing portions can be formed by moving up and down the cloth cutting knife 16 two or more times. The cloth cutting knife 16 is moved up and down at least once during formation of the stitches of the right and left side sewing portions. Also, the cloth cutting knife 16 is moved up and down once each time a given number of stitches of the right and left side sewing portions are formed. The given number of stitches is set in accordance with both of the length of the cutting edge of the cloth cutting knife 16 and the length of the buttonhole to be formed.Type: GrantFiled: June 26, 1998Date of Patent: December 26, 2000Assignee: Juki CorporationInventors: Mitsuhiro Tachikawa, Kazuaki Ishii, Yasuaki Hirano, Takashi Tsukioka, Toshiaki Kasuga, Tsuguo Kubota